Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450834 | 0.93 | KDM4E (0.47) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL21245644 | 0.81 | KDM4E (0.54) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL3060679 | 0.79 | KDM4E (0.48) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL1493280 | 0.79 | HTT (0.54) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL15283360 | 0.78 | KDM4E (0.51) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL28812142 | 0.78 | GPR119 (0.50) | KDM4EMAPTTHRBHTTGPR119 | |
| SCHEMBL17580484 | 0.77 | KDM4E (0.50) | KDM4EMAPTTHRBALDH1A1HPGD | |
| SCHEMBL30926528 | 0.77 | KDM4E (0.46) | KDM4EMAPTTHRBHPGDHTT | |
| SCHEMBL15174527 | 0.77 | TRPC6 (0.58) | KDM4EMAPTTHRBHTTGPR119 | |
| SCHEMBL15175760 | 0.77 | GPR119 (0.54) | KDM4EMAPTTHRBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| WO-2007044401-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060040958-A1 | Antiproliferative agents; anticancer agents; antiinflammatroy agents; Alzheimer's disease; viricides; fungicides | SCHERING CORPORATION | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040958-A1 | Antiproliferative agents; anticancer agents; antiinflammatroy agents; Alzheimer's disease; viricides; fungicides | CDK5, CDKN1A, CDK3 | KDM4E 340/4885MAPT 197/4885THRB 4550/4885 |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | KDM4E 1469/4885MAPT 4203/4885THRB 1418/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | KDM4E 679/4885MAPT 3188/4885THRB 3890/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | KDM4E 857/4885MAPT 1927/4885THRB 3492/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | KDM4E 1469/4885MAPT 4203/4885THRB 1418/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | KDM4E 1262/4885MAPT 2249/4885THRB 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.